Match tier Likely match
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-08-08

Lana Gettman

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Researcher

Also affiliated: Cooper Institute (1982)

Faculty Researcher

5 h-index 14 pubs 64 cited

  • Humans
  • Diabetes Mellitus, Type 2
  • Alzheimer Disease
  • Piperidines
  • Pharmaceutical Preparations
  • Pyridazines
  • SARS-CoV-2
  • COVID-19 Drug Treatment
  • Diabetes Mellitus
  • Diabetic Retinopathy
  • Glaucoma
  • Macular Degeneration
  • Macular Edema
  • Ocular Hypertension
  • Amyloid beta-Peptides

Biography and Research Information

OverviewAI-generated summary

Lana Gettman's research and publications focus on advancements in pharmaceutical treatments, particularly for chronic and infectious diseases. Her recent work includes reviews of novel drugs such as Lecanemab-irmb for Alzheimer's disease and Tirzepatide for type 2 diabetes. She has also published on Finerenone, Difelikefalin, and Avacopan, as well as Faricimab-svoa for macular degeneration and Omidenepag Isopropyl for glaucoma. Gettman has also contributed to the understanding of treatments for SARS-CoV-2, with publications detailing three novel therapies. Beyond drug development, her scholarly interests extend to pharmacy education, including a focus on implementing proactive support models to enhance student success and assessing skills in interpreting culture and sensitivity reports. Gettman's scholarship metrics include an h-index of 5 and 14 total publications.

Metrics

  • h-index: 5
  • Publications: 14
  • Citations: 64

Selected Publications

  • Developing professional etiquette and networking skills in pharmacy students: Evaluation of an etiquette dinner program (2026)
    Currents in Pharmacy Teaching and Learning DOI OpenAlex
  • Practicing and Assessing Skills of Interpreting Culture and Sensitivity Reports (2025)
    Scholar Works at Harding (Harding University Main Campus) OpenAlex
  • Lecanemab-irmb (Leqembi™) for Treatment of Alzheimer’s Disease (2024)
    The Senior Care Pharmacist 9 citations DOI OpenAlex
  • New Drugs: Faricimab-svoa (Vabysmo<sup>™</sup>) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti<sup>™</sup>) for Glaucoma and Ocular Hypertension (2023)
    The Senior Care Pharmacist DOI OpenAlex
  • New Drug: Tirzepatide (Mounjaro<sup>™</sup>) (2023)
    The Senior Care Pharmacist 7 citations DOI OpenAlex
  • New Drugs Update: Three Novel Treatments for SARS-CoV-2 (2022)
    The Senior Care Pharmacist DOI OpenAlex
  • New Drugs Update: Finerenone, Difelikefalin, and Avacopan (2022)
    The Senior Care Pharmacist 3 citations DOI OpenAlex
  • New Drugs (2021)
    The Senior Care Pharmacist DOI OpenAlex
  • Aspire to be smoke-free pilot study: A prevention educationaloutreach serving preschool children in rural Arkansas (2020)
    Tobacco Prevention & Cessation 1 citation DOI OpenAlex
  • Descriptive Analysis of Acceptance by Prescribers and Economic Benefit of Pharmacist Recommended Interventions in a Critical Care Unit (2018)
    INNOVATIONS in pharmacy 7 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

3 Collaborators 0 Institutions 0 Countries

Top Collaborators

View profile →
View profile →

Similar Researchers

Based on overlapping research topics